Home | About Us | Management | Capabilities | CME Research | QIE | Contact Us
News | Log In | Register

  • Academic CME QIE Offers
  • Applying PCSK9 Inhibitor Monoclonal Antibodies to Patients with Uncontrolled High LDL-C
  • Update on Pharmacological Cardiac Stress Testing: Efficacy, Risk Stratification, and Patient Selection
  • AAN 2014 Annual Meeting Highlights: Emerging Strategies in the Management of Multiple Sclerosis Patients
  • Strategies to Improve Stroke Prevention in Patients with Atrial Fibrillation
  • Managing the Critically-Ill Patient with Hyponatremia
  • Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis
Academic CME QIE Offers Applying PCSK9 Inhibitor Monoclonal Antibodies to Patients with Uncontrolled High LDL-C Update on Pharmacological Cardiac Stress Testing: Efficacy, Risk Stratification, and Patient Selection Advances in the Management of Patients with Obesity Strategies to Improve Stroke Prevention in Patients with Atrial Fibrillation Managing the Critically-Ill Patient with Hyponatremia Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis
Gallery Slideshow by WOWSlider.com v4.7

Latest Activities


Academic CME QIE OffersAcademic CME QIE Offers

AcademicCME is an accredited Medical Education and healthcare solutions company designed to impact practice behavior and most importantly, patient outcomes. The company's physician-based leadership enables insightful alignment between education and patient care. Courses offered act as a QIE catalyst, delivering learning based on identified performance gaps and facilitating practitioner collaboration ...



 

Applying PCSK9 Inhibitor Monoclonal Antibodies to Patients with Uncontrolled High LDL-CApplying PCSK9 Inhibitor Monoclonal Antibodies to Patients with Uncontrolled High LDL-C
1.00 AMA PRA Category 1 Credit(s) TM
The availability of more therapeutic options in the management of patients with dyslipidemia has opened an opportunity to evaluate clinical trial data, and the responsiveness to therapeutic agents. Evidence gathered via literature reviews ...


 

Update on Pharmacological Cardiac Stress Testing: Efficacy, Risk Stratification, and Patient SelectionUpdate on Pharmacological Cardiac Stress Testing: Efficacy, Risk Stratification, and Patient Selection
1.00 AMA PRA Category 1 Credit(s) TM
Given the rapidly evolving field of cardiac stress testing with respect to new risk stratification algorithms, new agents, and new assessment methods, it is difficult for physicians to remain up to date on the latest research and the benefits and risks ...


 

AAN 2014 Annual Meeting Highlights: Emerging Strategies in the Management of Multiple Sclerosis PatientsAAN 2014 Annual Meeting Highlights: Emerging Strategies in the Management of Multiple Sclerosis Patients
1.00 AMA PRA Category 1 Credit(s) TM
This Elsevier Medical Meeting Reporter will present and summarize important multiple sclerosis presentations and abstracts from the 66th Annual Meeting of the American Academy of Neurologists (AAN). AAN is the world’s largest professional association of neurologists with over 26,000 members and ...


 

Strategies to Improve Stroke Prevention in Patients with Atrial FibrillationStrategies to Improve Stroke Prevention in Patients with Atrial Fibrillation
1.00 AMA PRA Category 1 Credit(s) TM
Recent studies have changed the landscape and thinking on anticoagulation management and stroke prevention in patients with cardiac disease. Therapeutic options now include agents with unique modes of action and ...


 

 

Managing the Critically-Ill Patient with HyponatremiaManaging the Critically-Ill Patient with Hyponatremia
1.00 AMA PRA Category 1 Credit(s) TM
Hyponatremia is the most common electrolyte imbalance in hospitalized patients that is often misdiagnosed or undiagnosed due to its nonspecific symptoms. Early diagnosis and adequate treatment are crucial to prevent ...



 

Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic MyelofibrosisApplying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis
1.00 AMA PRA Category 1 Credit(s) TM
With the advent of JAK2 inhibitors, viable, clinically important treatment options are now becoming available and there is a clear need for focused educational efforts on the diagnosis and prognostic risk-based treatment ...